SAB Biotherapeutics Inc — 四半期キャッシュフロー (NASDAQ:SABS)

Financials

総資産 44.2 M38.12 M30.13 M183.45 M172.81 M 負債合計 18.23 M16.71 M18.11 M18.37 M21.32 M 純資産合計 25.97 M21.41 M12.02 M165.07 M151.49 M 負債および純資産合計 44.2 M38.12 M30.13 M183.45 M172.81 M 有利子負債合計 418.41 K3 M2.81 M2.87 M2.52 M 純負債 -20.34 M-9.85 M-2.9 M-108.01 M-94.07 M

ニュース

H.C. Wainwright、希薄化を理由にSAB Biotherapeuticsの目標株価を7ドルに引き下げ

H.C. Wainwright cuts SAB Biotherapeutics price target to $7 on dilution

SAB Biotherapeutics、第1相試験でC-ペプチドの初期シグナルを報告

SAB Biotherapeutics reports early C-peptide signals in phase 1 trial

UBSがSAB Biotherapeuticsの株式をバイ評価で開始、糖尿病薬の可能性に注目

SAB Biotherapeutics stock initiated with Buy rating at UBS on diabetes drug potential

グッゲンハイム、SAB Biotherapeuticsに1型糖尿病治療の可能性でBuy評価を開始

Guggenheim initiates SAB Biotherapeutics stock with Buy rating on T1D potential

SAB Biotherapeutics、取締役2名の辞任に伴い取締役会規模を縮小

SAB Biotherapeutics reduces board size following resignations of two directors

SAB Biotherapeuticsの株主、株式プラン修正とシリーズB転換提案を承認

SAB Biotherapeutics shareholders approve equity plan amendment and Series B conversion proposal